13th Pharmacovigilance 2017
In-Person Event
Sep 27 - 28, 2017
Chicago, Illinois, USA
OVERVIEW
13th Pharmacovigilance is organized by Virtue Insight and would be held during Sep 27 - 28, 2017 at Holiday Inn Chicago O'hare Area, Chicago, Illinois, United States of America.
The target audience for this medical event for CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:
• Pharmacovigilance
• Pharmacoepidemiology
• Pharmacogenomics
• Drug/Product Safety
• Drug Development
• Information and Clinical Data Management
• Clinical Pharmacology
• Clinical Safety
• Periodical safety update Reports
• Risk Management
• Research & Development
• Quality Assurance
• Patient Safety
• Signal Detection
• Safety Surveillance
• Outcomes Research
• Data Analysis
• Epidemiology
• Medical Affairs
• Regulatory Affairs and Compliance
• Information technology
• Sales and Marketing
13th Pharmacovigilance conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.
13th Pharmacovigilance 2017 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organizations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pv requirements, and to improve their organizations' compliance with pv requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue.
Key Speakers:
GERSON PELTZ, Senior Director - Oncology Safety Risk Lead, Pfizer
MELVA T. COVINGTON, Senior Director, Head of Field Based Medical Strategy, Sanofi
FATEMEH NOURI. E, Postdoctoral Fellow, FDA
DEEPA ARORA, Vice President - Pharmacovigilance & Global Head- Drug Safety & Risk Management,
Lupin (India)
KHAUDEJA BANO, Senior Medical Director, Medical Affairs, Abbott
BRUCE DONZANTI, Senior Group Director, Regulatory Pharmacovigilance Policy, Genentech
BRIAN DREYFUS, Director, Bristol-Myers Squibb
CARMIT STRAUSS, Global Risk Management Scientist / Safety Management - GPS, Amgen
BEN LOCWIN, Director, Global R&D, Biogen (& President, Healthcare Science Advisors)
ESTHER DE LA CUESTA, Senior Medical Director, Pharmacovigilance, Takeda Pharmaceuticals
BARBARA DA SILVA-TILLMANN, Senior Medical Director, Abbvie
GEORGE VAN BAELEN, Head Pharmacovigilance Latin America & Carribean, Shire
SHELLY GOODMAN, Head, Global Pharmacovigilance, Portola Pharmaceuticals
SHEETAL KHEDKAR, Senior Director, Regulatory Science, Sarah Cannon Development Innovations
ROBERT S. WALSH, Consultant, Walsh Medical Consulting
Plus many more
Key Themes:
• Establishing and streamlining pharmacovigilance in the US: where are we heading?
• Updates towards of legislation, policies, systems, technology, communication strategies and best practice in PV
• Why does pharmacovigilance sometimes fail and where?could the fault lie?
• Updates from the Office of Surveillance and Epidemiology (OSE) within CDER.
• Postmarketing safety monitoring within OSE
• Revised GVP guidance on signal management – how to implement?
• Updates to PSUR, PBRERs, DSUR, PASS
• Good Clinical Practices and Good Pharmacovigilance practices
• Future of outsourced phase I, II and III trials and post-marketing studies, inc. Pharmacovigilance
• Emerging technologies to efficiently collect, store and analyze data in a comprehensive data management system
• Patient centric approach to help improve patient safety
• Outsourcing activities - How to set it right?
• The effect of Brexit on Pharmacovigilance
What are the benefits of attending :
• Meet your peers in an interactive, discussion-based format designed to maximize knowledge transfer and networking
• Enjoy our informal networking at drinks and lunch
• Meet the leading solution providers in the market to forge partnerships and discover solutions
• Receive electronic versions of the conference documentation for use of reference post-event.
• Get ideas for?training topics?that you might want to present as professional development sessions to others in your workplace.
• Observe speakers from the perspective of seeing what works really well so you can learn new public speaking techniques and strategies that you can apply when doing your own presentations.
• Learn what not to do in presentations if you end up sitting through any sessions that fail to be engaging or informative.
• Delegates also benefit from discounted rates onfuture event attendance.
Additional details will be posted as soon as they are available.
The target audience for this medical event for CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:
• Pharmacovigilance
• Pharmacoepidemiology
• Pharmacogenomics
• Drug/Product Safety
• Drug Development
• Information and Clinical Data Management
• Clinical Pharmacology
• Clinical Safety
• Periodical safety update Reports
• Risk Management
• Research & Development
• Quality Assurance
• Patient Safety
• Signal Detection
• Safety Surveillance
• Outcomes Research
• Data Analysis
• Epidemiology
• Medical Affairs
• Regulatory Affairs and Compliance
• Information technology
• Sales and Marketing
13th Pharmacovigilance conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.
13th Pharmacovigilance 2017 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organizations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pv requirements, and to improve their organizations' compliance with pv requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue.
Key Speakers:
GERSON PELTZ, Senior Director - Oncology Safety Risk Lead, Pfizer
MELVA T. COVINGTON, Senior Director, Head of Field Based Medical Strategy, Sanofi
FATEMEH NOURI. E, Postdoctoral Fellow, FDA
DEEPA ARORA, Vice President - Pharmacovigilance & Global Head- Drug Safety & Risk Management,
Lupin (India)
KHAUDEJA BANO, Senior Medical Director, Medical Affairs, Abbott
BRUCE DONZANTI, Senior Group Director, Regulatory Pharmacovigilance Policy, Genentech
BRIAN DREYFUS, Director, Bristol-Myers Squibb
CARMIT STRAUSS, Global Risk Management Scientist / Safety Management - GPS, Amgen
BEN LOCWIN, Director, Global R&D, Biogen (& President, Healthcare Science Advisors)
ESTHER DE LA CUESTA, Senior Medical Director, Pharmacovigilance, Takeda Pharmaceuticals
BARBARA DA SILVA-TILLMANN, Senior Medical Director, Abbvie
GEORGE VAN BAELEN, Head Pharmacovigilance Latin America & Carribean, Shire
SHELLY GOODMAN, Head, Global Pharmacovigilance, Portola Pharmaceuticals
SHEETAL KHEDKAR, Senior Director, Regulatory Science, Sarah Cannon Development Innovations
ROBERT S. WALSH, Consultant, Walsh Medical Consulting
Plus many more
Key Themes:
• Establishing and streamlining pharmacovigilance in the US: where are we heading?
• Updates towards of legislation, policies, systems, technology, communication strategies and best practice in PV
• Why does pharmacovigilance sometimes fail and where?could the fault lie?
• Updates from the Office of Surveillance and Epidemiology (OSE) within CDER.
• Postmarketing safety monitoring within OSE
• Revised GVP guidance on signal management – how to implement?
• Updates to PSUR, PBRERs, DSUR, PASS
• Good Clinical Practices and Good Pharmacovigilance practices
• Future of outsourced phase I, II and III trials and post-marketing studies, inc. Pharmacovigilance
• Emerging technologies to efficiently collect, store and analyze data in a comprehensive data management system
• Patient centric approach to help improve patient safety
• Outsourcing activities - How to set it right?
• The effect of Brexit on Pharmacovigilance
What are the benefits of attending :
• Meet your peers in an interactive, discussion-based format designed to maximize knowledge transfer and networking
• Enjoy our informal networking at drinks and lunch
• Meet the leading solution providers in the market to forge partnerships and discover solutions
• Receive electronic versions of the conference documentation for use of reference post-event.
• Get ideas for?training topics?that you might want to present as professional development sessions to others in your workplace.
• Observe speakers from the perspective of seeing what works really well so you can learn new public speaking techniques and strategies that you can apply when doing your own presentations.
• Learn what not to do in presentations if you end up sitting through any sessions that fail to be engaging or informative.
• Delegates also benefit from discounted rates onfuture event attendance.
Additional details will be posted as soon as they are available.
KEY DATES
27 Sep, 2017
Event Start Date
28 Sep, 2017
Event End Date
SPECIALITIES
Pharmacy and MedicineClinical PharmacologySUGGESTED HOTELS
CONFERENCE VENUE
Holiday Inn Chicago O'hare AreaRELATED CONFERENCES & LIVE WEBINARS
Quick Links